How Long Does KGF Stay in Your System? What the Pharmacokinetic Literature Reports

The short answer, and why it is not a single number

People asking how long keratinocyte growth factor "stays in the system" are usually asking three different questions at once: how quickly the protein disappears from blood, how long its biological effects last in tissue, and whether it shows up on a test. The published literature answers these separately, and only the first one is a pharmacokinetic question in the strict sense.

Keratinocyte growth factor is not one molecule. KGF-1 (FGF7) is the original epithelial mitogen; KGF-2 (FGF10) is a related family member; and the recombinant therapeutic versions studied in humans — palifermin (a truncated recombinant human KGF-1) and repifermin (recombinant KGF-2) — are engineered proteins with their own disposition profiles. Pharmacokinetic parameters measured for one of these do not automatically transfer to another, and they certainly do not transfer to a research-grade preparation of unverified composition.

The most directly relevant compound-specific work in the verified literature set is the report describing the pharmacologic and pharmacokinetic profile of repifermin (KGF-2) in monkeys with comparative pharmacokinetics in humans (PMID 12102617), and the clinical pharmacology study of pharmacokinetic and pharmacodynamic interactions between palifermin and heparin (PMID 25880826). Everything else on this page is either a different kind of KGF study — biological effect rather than clearance — or general protein pharmacology that is labelled as such.

What the KGF-specific pharmacokinetic studies actually measured

Repifermin (KGF-2): cross-species pharmacokinetics

The study describing repifermin in monkeys reported both a pharmacologic and a pharmacokinetic profile and set those animal data alongside comparative human pharmacokinetics (PMID 12102617). This is the structure typical of early drug-development pharmacology: intravenous administration in a non-human primate, serial plasma sampling, and then a bridge to human exposure data. Because the analysis spanned two species, it is one of the few places in the KGF literature where researchers addressed clearance and exposure directly rather than inferring persistence from a downstream biological readout.

Palifermin: clearance in the presence of heparin

Keratinocyte growth factor is a heparin-binding protein, which makes interaction with heparin a clinically meaningful pharmacokinetic question rather than an academic one. Researchers examined pharmacokinetic and pharmacodynamic interactions between palifermin and heparin in a clinical pharmacology study (PMID 25880826). The relevance to "how long does it stay" is direct: binding partners in blood and on cell surfaces change the volume a protein distributes into and the rate at which it is removed, so co-administered heparin is a plausible modifier of measured exposure. That study is the appropriate primary source for the numeric parameters; this page does not reproduce figures beyond the scope of the cited abstracts.

What the other KGF papers were designed to answer

Most KGF research measured tissue biology, not blood levels. Researchers reported that KGF protected against Pseudomonas aeruginosa-induced lung injury in an animal model (PMID 11076810), that KGF-2 inhibited bacterial infection with Pseudomonas aeruginosa pneumonia in a mouse model (PMID 26617350), and that KGF-2 targeted alveolar epithelia and capillary endothelia to reduce high-altitude pulmonary oedema in rats (PMID 22568566). A separate study reported that keratinocyte growth factor improved alterations of lung permeability and bronchial epithelium in allergic rats (PMID 17392324). None of these were clearance studies, and reading a duration of benefit in them as a half-life would be a category error.

Plasma clearance versus duration of effect

For growth factors, the molecule can be gone long before its consequences are. KGF acts on epithelial FGFR2b-bearing cells and initiates transcriptional programmes — proliferation, migration, cytoprotection — that continue after the ligand has been cleared or internalised.

Two findings in the verified set illustrate the gap. Researchers reported that keratinocyte growth factor augmented pulmonary innate immunity through epithelium-driven, GM-CSF-dependent paracrine activation of alveolar macrophages (PMID 21343299) — an indirect, second-messenger-style cascade in which one cell type is stimulated and a different cell type carries the effect forward. Similarly, a 2025 study reported that mesenchymal stem cell-secreted KGF ameliorated acute lung injury via the Gab1/ERK/NF-κB signalling axis (PMID 40640718), again describing a signalling pathway rather than a residence time. Signalling cascades and tissue remodelling operate on timescales set by cell biology, not by plasma elimination.

General protein pharmacokinetics (not KGF-specific measurements)

Where compound-specific data are absent, the following principles come from general protein and peptide pharmacology and are presented as background, not as findings about KGF:

• Proteins are cleared by catabolism, not by hepatic CYP metabolism. Recombinant growth factors are broken down to amino acids by proteases in plasma, endothelium, liver, kidney and target tissue, and the fragments enter the normal amino-acid pool.
• Receptor-mediated clearance is concentration-dependent. When a ligand is removed partly by binding and internalisation at its own receptor, elimination can be non-linear: the apparent half-life may differ across exposure ranges.
• Route dominates the early profile. Intravenous administration produces an immediate peak and a distribution phase; subcutaneous or local administration produces a slower rise and a depot effect in which absorption, not elimination, controls how long the molecule is measurable.
• Matrix binding creates local reservoirs. Heparin-binding growth factors associate with heparan sulfate proteoglycans in basement membrane and extracellular matrix, which slows diffusion away from tissue.

That last point is not purely theoretical for KGF. Researchers designing a fusion keratinocyte growth factor containing a collagen-binding domain for tissue-engineering application used in silico methods precisely because anchoring the protein to matrix is a recognised strategy for extending local residence (PMID 36308945). Matrix context matters to epithelial biology more broadly: one study reported that laminin α5 in the keratinocyte basement membrane was required for epidermal–dermal intercommunication (PMID 27234307).

Factors that plausibly change how long KGF persists

1. Which molecule it is. KGF-1, KGF-2 and their truncated recombinant analogues differ in sequence, charge and heparin affinity; the repifermin analysis addressed KGF-2 specifically (PMID 12102617).
2. Co-administered heparin. The clinical study of palifermin and heparin was designed around exactly this interaction (PMID 25880826).
3. Species. Cross-species scaling was an explicit part of the repifermin work, comparing monkey and human pharmacokinetics (PMID 12102617).
4. Delivery route and formulation. Local and inhaled delivery systems change residence entirely; one study reported that an inhaled mRNA nanoformulation with biogenic ribosomal protein reversed established pulmonary fibrosis in a bleomycin-induced murine model (PMID 35146813), an example of a delivery platform rather than a systemic protein injection.
5. Renal and hepatic function. General protein pharmacology, not a KGF-specific measurement: organs responsible for catabolism and filtration influence clearance of small proteins.
6. Target-tissue receptor density. Where receptor-mediated uptake contributes, tissues rich in FGFR2b-expressing epithelium represent a sink. Model systems that reconstruct epithelial–stromal architecture exist partly for this reason; researchers bioengineering human intestinal mucosa reported that stromal support mattered for pharmacological evaluation in vitro (PMID 39594608).

Detectability and drug testing: what is and is not screened

Stated plainly: standard workplace and clinical drug panels do not test for keratinocyte growth factor. Five- and ten-panel urine screens are immunoassays built for small-molecule drugs of abuse — cannabinoids, opioids, amphetamines, cocaine metabolites, benzodiazepines, phencyclidine and similar analytes. A recombinant growth factor shares no chemistry with those targets and would not cross-react into a positive result.

Routine clinical chemistry does not measure it either. Detecting an exogenous recombinant growth factor requires a purpose-built immunoassay or mass-spectrometry method, of the kind used inside pharmacokinetic studies themselves — the repifermin and palifermin programmes necessarily used bioanalytical assays to generate their exposure data (PMID 12102617, PMID 25880826). Those assays are research and drug-development tools, not services offered on a standard requisition form.

Anti-doping testing is a separate framework. The World Anti-Doping Agency's prohibited list includes a category covering growth factors and growth factor modulators, and fibroblast growth factors are named within it; the list is revised annually, so the current published version is the only authoritative reference for what is in scope in a given year. Detection capability for protein growth factors is an active analytical-chemistry problem and differs from one substance to another. This paragraph describes a regulatory framework, not a study finding.

Regulatory context

Palifermin is a recombinant human keratinocyte growth factor approved as a prescription biologic; it is the form with the most formal clinical pharmacology behind it, including the heparin interaction analysis (PMID 25880826). Repifermin (KGF-2) was investigated but did not reach approval; its published profile remains a development-stage dataset (PMID 12102617). Materials sold as "KGF" outside the pharmaceutical supply chain are generally labelled research use only, are not subject to the identity, purity and potency controls applied to approved biologics, and have no published pharmacokinetic characterisation of their own.

Pharmacokinetic Findings and Tolerability: What Studies Report

The verified pharmacokinetic literature in this set is narrow. The palifermin study reported pharmacokinetic and pharmacodynamic interactions with heparin in a clinical setting (PMID 25880826), and the repifermin study reported a pharmacologic and pharmacokinetic profile in monkeys with comparative human pharmacokinetics (PMID 12102617); readers wanting adverse-event detail should consult those primary reports and the approved product labelling rather than inferring tolerability from animal efficacy papers such as the Pseudomonas lung-injury models (PMID 11076810, PMID 26617350). No adverse-event frequencies are reproduced here because they fall outside the scope of the cited abstracts.

Limitations of the evidence

Three limitations shape any answer to this question. First, the animal literature dominates and was built around biological endpoints in lung and epithelium rather than clearance (PMID 22568566, PMID 17392324). Second, the two molecules with human pharmacokinetic data are specific engineered recombinants, not generic "KGF". Third, effect duration and molecular persistence diverge, as the paracrine and signalling-axis studies illustrate (PMID 21343299, PMID 40640718).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any question relating to medicines, testing or health.

Related reading

For background on the molecule itself, see KGF. For the cross-compound framework behind these questions, see how long peptides stay in your system.

References

• Pharmacologic and pharmacokinetic profile of repifermin (KGF-2) in monkeys and comparative pharmacokinetics in humans (AAPS PharmSci, 2002)
• Pharmacokinetic and pharmacodynamic interactions between palifermin and heparin (Journal of Clinical Pharmacology, 2015)
• Mesenchymal stem cell-secreted KGF ameliorates acute lung injury via the Gab1/ERK/NF-κB signaling axis (Cellular & Molecular Biology Letters, 2025)
• Keratinocyte growth factor improves alterations of lung permeability and bronchial epithelium in allergic rats (European Respiratory Journal, 2007)
• Inhaled mRNA Nanoformulation with Biogenic Ribosomal Protein Reverses Established Pulmonary Fibrosis in a Bleomycin-Induced Murine Model (Advanced Materials, 2022)
• Keratinocyte growth factor-2 inhibits bacterial infection with Pseudomonas aeruginosa pneumonia in a mouse model (Journal of Infection and Chemotherapy, 2016)
• Keratinocyte growth factor protects against Pseudomonas aeruginosa-induced lung injury (American Journal of Physiology. Lung Cellular and Molecular Physiology, 2000)
• KGF-2 targets alveolar epithelia and capillary endothelia to reduce high altitude pulmonary oedema in rats (Journal of Cellular and Molecular Medicine, 2012)
• Bioengineering the Human Intestinal Mucosa and the Importance of Stromal Support for Pharmacological Evaluation In Vitro (Cells, 2024)
• In silico design of fusion keratinocyte growth factor containing collagen-binding domain for tissue engineering application (Journal of Molecular Graphics & Modelling, 2023)
• Laminin α5 in the keratinocyte basement membrane is required for epidermal-dermal intercommunication (Matrix Biology, 2016)
• Keratinocyte growth factor augments pulmonary innate immunity through epithelium-driven, GM-CSF-dependent paracrine activation of alveolar macrophages (Journal of Biological Chemistry, 2011)